Results 161 to 170 of about 76,191 (305)
Clinical studies on GVHD in HLA compatible allogenic bome marrow transplantation.
TAKEHISA MORISHITA
openalex +2 more sources
Donor natural killer (NK1.1+) cells do not play a role in the suppression of GVHD or in the mediation of GVL reactions after DLI [PDF]
Bryon D. Johnson+4 more
openalex +1 more source
Volatile organic compounds (VOCs) are generated during pathologic processes, and their assessment can be used to diagnose and monitor a variety of diseases.
Betty K. Hamilton+14 more
doaj
THE MECHANISM OF IL-2-MEDIATED PROTECTION AGAINST GVHD IN MICE
Megan Sykes, Varghese Abraham
openalex +1 more source
Patient‐derived xenografts (PDXs) can be improved by implantation of a humanized niche. We tested different biomaterials and approaches, and demonstrate that the combination of an injectable biomaterial for scaffold creation plus an intravenous route for acute myeloid leukemia (AML) xenotransplantation provide the most convenient and robust approach to
Daniel Busa+13 more
wiley +1 more source
A novel “prof” cocktail therapy is designed. It screens antigens, selects personalized antigen panels, engineers optimized CAR‐Vδ1 T cells, and tests in patient‐derived GBM organoids, offering hope for effective CAR‐T drugs against heterogeneous solid tumors. Abstract Various challenges, including tumor heterogeneity and inadequate T cell infiltration,
Guidong Zhu+12 more
wiley +1 more source
Spontaneous activation of JNK-1 and PI-3 kinase can be induced in lupus-like chronic GVHD in the P->F1 model [PDF]
Florin Niculescu+4 more
openalex +1 more source